Travere Therapeutics (TVTX) insider files to sell shares under Rule 144

Rhea-AI Filing Summary

Christopher Cline filed a notice of proposed sale of Travere Therapeutics common stock under Rule 144. The filing covers 1,745 common shares with an aggregate market value of $56,165.62, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ around 02/04/2026.

The shares were acquired as restricted stock from the issuer on 01/31/2026. In the past three months, Cline also sold 20,000 common shares for gross proceeds of $700,200.00 and 7,242 common shares for gross proceeds of $232,616.03.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1745	56165.62	89472327	02/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/31/2026	Restricted Stock	Issuer			1745	01/31/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
CHRISTOPHER CLINE 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	12/01/2025	20000	700200.00
CHRISTOPHER CLINE 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	02/03/2026	7242	232616.03

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for TVTX disclose about Christopher Cline?

The filing discloses that Christopher Cline intends to sell 1,745 Travere Therapeutics common shares under Rule 144. These shares were acquired as restricted stock from the issuer on January 31, 2026, and are planned for sale on NASDAQ through Morgan Stanley Smith Barney LLC.

How many Travere Therapeutics (TVTX) shares are covered by the new planned Rule 144 sale?

The notice covers a proposed sale of 1,745 Travere Therapeutics common shares. The aggregate market value of these shares is listed as $56,165.62, with Morgan Stanley Smith Barney LLC acting as broker and the shares expected to trade on NASDAQ around February 4, 2026.

What prior share sales by Christopher Cline in TVTX are reported in the last three months?

The filing reports two prior sales of Travere Therapeutics common shares in the last three months. Cline sold 20,000 shares on December 1, 2025 for $700,200.00 and 7,242 shares on February 3, 2026 for gross proceeds of $232,616.03.

How and when did Christopher Cline acquire the Travere Therapeutics (TVTX) shares being sold?

The 1,745 Travere Therapeutics shares were acquired as restricted stock from the issuer on January 31, 2026. The filing lists the nature of the acquisition as “Restricted Stock,” with the same date shown for acquisition and payment and “Not Applicable” for the nature of payment.

On which exchange and through which broker will the TVTX shares be sold under this Form 144?

The proposed Rule 144 sale will be executed on NASDAQ, according to the filing. Morgan Stanley Smith Barney LLC Executive Financial Services, based at 1 New York Plaza, New York, is named as the broker handling the planned sale of 1,745 common shares.

How many Travere Therapeutics (TVTX) common shares are outstanding in this Form 144 notice?

The notice states that 89,472,327 Travere Therapeutics common shares are outstanding. This figure provides context for the planned Rule 144 sale of 1,745 shares, showing the relative size of the proposed transaction compared with the total shares outstanding.